Trial Profile
Assessment of the effect of adalimumab on response to influenza virus and pneumococcal vaccines in subjects with rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Influenza virus vaccine; Pneumococcal vaccines
- Indications Influenza virus infections; Pneumococcal infections; Rheumatoid arthritis
- Focus Pharmacodynamics
- Sponsors Abbott Laboratories
- 23 Jun 2016 Results of safety analysis of this and other trials published in the Annals of the Rheumatic Diseases.
- 16 Apr 2008 New trial record.